1:41
Applying the right therapies to the right AML patient population
Christoph Röllig
1:28
The role of Cure Leukemia in improving access to clinical trials for patients
Charles Craddock
T-cell lymphoma: autologous or allogeneic transplant?
Francine Foss
2:27
What are the challenges of integrating therapy around autologous transplantation?
John Kuruvilla
1:03
What is induction therapy for autologous stem cell transplanation?
Michele Cavo
4:59
Conflicting results of the EMN02 and staMINA trials
Michele Cavo
2:50
Current standard of care for patients who are eligible for autologous stem cell transplantation
Michele Cavo
1:57
Promising new combinations in the treatment of myeloma
Evangelos Terpos
1:48
Managing problems in treating CLL
Anna Schuh
1:18
Treatment options for leukemia patients who fail the standard of care
Paolo Ghia
1:13
Have novel drugs made stem cell transplantation obsolete?
David Maloney
3:51
Celebrating 60 years of successful allogeneic transplant at EHA 2017
Mohamad Mohty
5:22
Lymphoid Highlights from BSH 2017
George Follows
2:27
Indications for the use of brentuximab vedotin in relapsed/refractory Hodgkin lymphoma
Anna Sureda
3:31
Advances in multiple myeloma treatment over the last years
Vincent Rajkumar
16:48
COMy 2017: Day 2 discussion on relapsed myeloma, treatment, plasma cell leukemia and awards
Arnon Nagler et al.
VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

VJHO needs the contact information you provide to inform you about our latest hemonc news and videos, educational courses and industry supported content (some of which may be promotional in nature). You may unsubscribe from these communications at anytime. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy.

The content of VJHemOnc is intended for healthcare professionals